A 64-year-old man presents with an NSTEMI and undergoes successful PCI with a drug-eluting stent to the proximal left anterior descending artery. He is discharged on acetylsalicylic acid (ASA) 81 mg daily, high-intensity statin, ACE inhibitor, and beta-blocker. According to Canadian antiplatelet guidance, what additional antiplatelet regimen is most appropriate?